Polymorphisms of the CYP2D6 gene and its relationship with Plasmodium vivax relapses after chloroquine-primaquine treatment in Turbo, Colombia
Background: Plasmodium vivax relapse due to hypnozoites represents a significant mechanism for parasite persistence in the population. Primaquine (PQ), the drug of choice for eliminating hypnozoites, requires metabolic activation by Cytochrome P450-2D6 (CYP2D6). Genetic variations in CYP2D6 can alte...
- Autores:
-
Sierra Cifuentes, Veronica
Zuluaga Idárraga, Lina María
Aguirre Acevedo, Daniel Camilo
Silva de Barros Puça, María Carolina
Nobrega de Sousa, Tais
Lopera Mesa, Tatiana María
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2025
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/46861
- Acceso en línea:
- https://hdl.handle.net/10495/46861
- Palabra clave:
- Citocromo P-450 CYP2D6
Cytochrome P-450 CYP2D6
Malaria
Sistema Enzimático del Citocromo P-450
Cytochrome P-450 Enzyme System
Plasmodium vivax
Primaquina
Primaquine
Recurrencia
Recurrence
https://id.nlm.nih.gov/mesh/D019389
https://id.nlm.nih.gov/mesh/D008288
http://id.nlm.nih.gov/mesh/D003577
https://id.nlm.nih.gov/mesh/D010966
https://id.nlm.nih.gov/mesh/D011319
http://id.nlm.nih.gov/mesh/D012008
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/4.0/
| Summary: | Background: Plasmodium vivax relapse due to hypnozoites represents a significant mechanism for parasite persistence in the population. Primaquine (PQ), the drug of choice for eliminating hypnozoites, requires metabolic activation by Cytochrome P450-2D6 (CYP2D6). Genetic variations in CYP2D6 can alter PQ metabolism, potentially increasing the risk of relapses. This study aimed to determine CYP2D6 polymorphisms in subjects with Plasmodium vivax under supervised chloroquine-primaquine treatment and explore their association with relapses and PQ plasma levels. Methods: CYP2D6 phenotypes and genotypes were successfully determined for 71 out of 78 patients included in the study. Nine polymorphisms (SNPs and indels) and gene copy number variation were analyzed. The association between the CYP2D6 phenotype, P. vivax relapse over six months follow-up, and PQ plasma levels were explored. Results: Most diplotypes (81.7 %) were associated with normal (gNM-F) and ultrarapid (gUM) CYP2D6 metabolizers, while 18.3 % were associated with poor (gPM) and intermediate (gIM and gNM-S) metabolizers. The median plasma PQ concentration on day 2 was higher in impaired CYP2D6 activity group (poor/intermediate) compared normal metabolizers (normal/ultrarapid) (660.4 ng/ml vs 313.5 ng/ml; effect size r -0.51, 95 % CI -0.82 to 0.03). No significant difference was found in the hazard ratio (HR) of relapse between impaired and normal CYP2D6 activity (adjusted HR: 1.45; 95 % CI: 0.39-5.39). Conclusion: Impaired CYP2D6 activity phenotypes were frequent in individuals infected with P. vivax from an endemic region of Colombia. Further research is essential to elucidate the relationship between these phenotypes and P. vivax relapses, as suggested by this exploratory study. |
|---|
